Liminatus Pharma, Inc. Class A Common Stock (LIMN)
US — Healthcare Sector
Automate Your Wheel Strategy on LIMN
With Tiblio's Option Bot, you can configure your own wheel strategy including LIMN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
Liminatus Pharma, Inc. (NASDAQ: LIMN) Signs MOU with Capital Trust Group for USD 30 Million Equity Investment via an earn-out mechanism and Future Strategic Cooperation
LIMN
Published: October 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
Published: October 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
LA PALMA, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN), a clinical-stage immuno-oncology company developing next-generation CD47-blockade therapies, announced today that it has entered into a Memorandum of Understanding (MOU) with Capital Trust Group Limited (CTG), a New Zealand-based investment management firm, for a USD 30,000,000 equity financing via an earn-out mechanism to support Liminatus's research and development of advanced immunotherapy assets.
Read More
About Liminatus Pharma, Inc. Class A Common Stock (LIMN)
- IPO Date 2025-05-01
- Website https://liminatuspharma.com
- Industry Biotechnology
- CEO Chris Kim
- Employees 3
Liminatus Pharma, Inc. operates as a clinical-stage immuno-oncology company that develops novel cancer therapies. The company is based in LA Palma, California.